Sinovant Sciences is
an innovative biopharmaceutical company based in Shanghai, Beijing and Hongkong. We are
dedicated to creating unique value for the Chinese biopharma industry.
Sinovant Sciences has a
diverse pipeline of 11 therapeutic candidates in the areas of infectious
diseases, oncology, and general medicine, including three late-stage
therapeutics: lefamulin, vibegron, and derazantinib. In addition to the three
registrational programs below, Sinovant Sciences is also exploring development of other
indications and has the rights to eight other earlier-stage therapeutics
targeting significant unmet needs in a broad range of therapeutic areas.